Hyperactivation of the pathway due to PTEN deficiency or activating mutations in the catalytic subunit alpha of phosphatidylinositol-3-kinase (PIK3CA) and in AKT1 is implicated in tumor growth across cancer indications [3]; hence, the PI3K/AKT pathway has been a target of oncology drug discovery [1, 2, 4]. Here, AKT1 is linked to neoplasm.